169 related articles for article (PubMed ID: 27745798)
41. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
42. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
43. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.
Hsu M; Sasaki M; Igarashi S; Sato Y; Nakanuma Y
Cancer; 2013 May; 119(9):1669-74. PubMed ID: 23335286
[TBL] [Abstract][Full Text] [Related]
44. Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.
Bennani B; Gilles S; Fina F; Nanni I; Ibrahimi SA; Riffi AA; Nejjari C; Benajeh DA; El Abkari M; Martin PM; Ouafik L
Int J Biol Markers; 2010; 25(4):179-84. PubMed ID: 21161938
[TBL] [Abstract][Full Text] [Related]
45. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
46. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
47. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
48. Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.
Bidinotto LT; Véo CA; Loaiza EA; De França AP; Lorenzi AT; Rosa LA; De Oliveira CM; Levi JE; Scapulatempo-Neto C; Longatto-Filho A; Reis RM
Mol Med Rep; 2016 Oct; 14(4):3791-7. PubMed ID: 27573925
[TBL] [Abstract][Full Text] [Related]
49. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
50. Investigating KRAS/BRAF mutation in oropharyngeal squamous cell carcinomas: a preliminary study.
Küçük Ü; Bayol Ü; Usturalı Keskin E; Pala EE; Çukurova İ; Çolak MA; Değirmenci M; Özer Ö; Koç A
Kulak Burun Bogaz Ihtis Derg; 2016; 26(5):265-7. PubMed ID: 27888823
[TBL] [Abstract][Full Text] [Related]
51. KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
Zhou L; Baba Y; Kitano Y; Miyake K; Zhang X; Yamamura K; Kosumi K; Kaida T; Arima K; Taki K; Higashi T; Imai K; Hashimoto D; Yamashita Y; Chikamoto A; Beppu T; Tan X; Baba H
Med Oncol; 2016 Apr; 33(4):32. PubMed ID: 26927447
[TBL] [Abstract][Full Text] [Related]
52. Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers.
Kwon MJ; Kim JW; Jeon JY; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Min KW; Choe JY; Lee HK
Pathol Res Pract; 2017 Apr; 213(4):381-388. PubMed ID: 28214200
[TBL] [Abstract][Full Text] [Related]
53. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
54. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression.
Tanaka M; Kunita A; Yamagishi M; Katoh H; Ishikawa S; Yamamoto H; Abe J; Arita J; Hasegawa K; Shibata T; Ushiku T
Liver Int; 2022 Oct; 42(10):2329-2340. PubMed ID: 35833881
[TBL] [Abstract][Full Text] [Related]
55. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.
Jang S; Chun SM; Hong SM; Sung CO; Park H; Kang HJ; Kim KP; Lee YJ; Yu E
Mod Pathol; 2014 May; 27(5):731-9. PubMed ID: 24186137
[TBL] [Abstract][Full Text] [Related]
56. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
57. [Prognosis after resection of intrahepatic cholangiocarcinoma: clinical significance of KRAS mutations].
Schneider MA; Büchler MW
Chirurg; 2022 Mar; 93(3):306-307. PubMed ID: 35175401
[No Abstract] [Full Text] [Related]
58. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma.
Topham JT; Tsang ES; Karasinska JM; Metcalfe A; Ali H; Kalloger SE; Csizmok V; Williamson LM; Titmuss E; Nielsen K; Negri GL; Spencer Miko SE; Jang GH; Denroche RE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Loree JM; Notta F; Wilson JM; Bathe OF; Tang PA; Goodwin R; Morin GB; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Schaeffer DF; Renouf DJ
Nat Commun; 2022 Oct; 13(1):5941. PubMed ID: 36209277
[TBL] [Abstract][Full Text] [Related]
59. Mouse Model for Cholangiocarcinoma from Peribiliary Glands.
Nakagawa H; Suzuki N; Koike K
Methods Mol Biol; 2019; 1905():237-245. PubMed ID: 30536105
[TBL] [Abstract][Full Text] [Related]
60. Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma.
Guo B; Friedland SC; Alexander W; Myers JA; Wang W; O'Dell MR; Getman M; Whitney-Miller CL; Agostini-Vulaj D; Huber AR; Mello SS; Vertino PM; Land HK; Steiner LA; Hezel AF
Cell Rep; 2022 Aug; 40(9):111253. PubMed ID: 36044839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]